PULSE-SED Puts Anesthesia Strategy at the Center of Pulsed Field Ablation
A new randomized trial is asking a practical question that has shadowed the spread of pulsed field ablation into routine electrophysiology: does every patient need general anesthesia, or can local anesthesia with conscious sedation deliver the same rhythm-control result with less procedural burden?
The PULSE-SED study is designed as a prospective, multicenter, randomized, controlled, noninferiority trial in adults with paroxysmal atrial fibrillation. It will enroll 390 participants between 18 and 80 years of age and assign them in a 1:1 ratio to either conscious sedation with local anesthesia or general anesthesia. All participants will undergo the same ablation platform, using the VARIPULSE pulsed field ablation catheter with CARTO 3 electroanatomic mapping guidance. The question is not whether pulmonary vein isolation works in principle. The question is whether the anesthesia frame around the procedure can be simplified without giving up safety, tolerability, or arrhythmia control.
Why the Anesthesia Choice Matters in Pulsed Field Ablation
Pulsed field energy is attractive because it is designed to create myocardial injury through nonthermal mechanisms, but the procedure still creates real bedside challenges. Chest discomfort, coughing, involuntary movement, and phrenic nerve stimulation can interrupt catheter stability and make patient tolerance unpredictable. In many centers, those problems have pushed practice toward general anesthesia, which offers immobility and airway control at the cost of more personnel, more resources, and longer recovery logistics.
A single sentence captures the operational tension: the more controlled the room, the heavier the machinery around it.
Conscious sedation with local anesthesia could change that balance. If it maintains patient comfort and procedural stability, it may reduce the anesthesia footprint while preserving the technical quality of lesion delivery. That is especially relevant in high-volume electrophysiology programs, where time in the lab, recovery flow, and staffing pressures all shape access to care. The protocol is built around that assumption, but it does not take the shortcut of asserting equivalence. Instead, it uses a prespecified noninferiority design to test whether the less intensive approach stays within an acceptable margin.
Primary Endpoint Focuses on Rhythm Recurrence, Not Just Procedural Ease
The primary outcome is recurrence of an electrocardiographically documented atrial tachyarrhythmia after an 8-week blanking period, with recurrence defined as atrial fibrillation, atrial flutter, or atrial tachycardia lasting at least 30 seconds through 12 months after ablation. The trial will judge whether conscious sedation is noninferior to general anesthesia using an absolute margin of 13 percentage points.
That endpoint keeps the study anchored to what matters most in atrial fibrillation care: durable rhythm suppression. A comfortable procedure has value only if it still produces lesion sets that hold over time. The blanking period reflects standard electrophysiology practice, allowing early inflammatory or transient arrhythmias to settle before long-term efficacy is counted. By extending surveillance to 12 months, the study places long-term rhythm durability ahead of short-term convenience.
The Procedural Design Leaves Little Room for Mixed Signals
Every participant will receive bilateral pulmonary vein isolation. Additional ablation of the left atrial posterior wall, superior vena cava, or other atrial substrate may be performed when clinically indicated, which preserves some flexibility for operator judgment while keeping the backbone of the procedure consistent across groups. During left atrial ablation, activated clotting time will be maintained at 350 seconds or longer, a standard safeguard against thromboembolic complications during left-sided catheter work.
The sedation arm is not a loose, improvised approach. It includes protocol-specified antitussive pretreatment, local anesthesia, analgesia, and conscious sedation, with additional medication permitted according to vital signs, pain, coughing, agitation, and clinical tolerance. Compound methoxyphenamine capsules, salbutamol, budesonide, lidocaine, fentanyl, midazolam, tropisetron hydrochloride, dexamethasone, and atropine appear in the medication list, reflecting a strategy built to blunt cough, pain, bronchospasm, nausea, and autonomic instability. Persistent severe coughing, agitation, respiratory depression, refractory hypoxemia, or hemodynamic instability can trigger conversion to general anesthesia. Even then, those participants remain in their original assignment for intention-to-treat analysis, preserving the integrity of the comparison.
Safety, Conversion, and Recovery Are Built Into the Secondary Endpoints
The secondary endpoints widen the lens beyond rhythm recurrence. Investigators will compare successful completion of the planned ablation procedure under the assigned anesthesia strategy, conversion from conscious sedation to general anesthesia, anesthesia-related adverse events, ablation-related complications, acute pulmonary vein isolation success, procedure and recovery times, fluoroscopy time, patient-reported pain and anxiety, overall procedural experience, and direct anesthesia- or sedation-related medical costs.
This matters because the real-world value of sedation cannot be judged by efficacy alone. A strategy that reduces staffing demands but increases patient movement, failed completion, or recovery instability would not represent progress. Likewise, if general anesthesia improves catheter stability but slows throughput and adds cost without improving arrhythmia control, the tradeoff may be hard to justify in settings where resources are limited. The trial is set up to expose those differences directly rather than inferring them from workflow assumptions.
A Trial Shaped by Operational Realities in Electrophysiology
Participants will be followed at 1, 2, 3, 6, and 12 months after ablation, with wearable electrocardiographic monitoring for at least 7 days at each scheduled visit. That repeated surveillance should improve detection of intermittent arrhythmias that routine clinic ECGs often miss. In atrial fibrillation trials, the way recurrence is measured can shape the apparent success of the procedure as much as the procedure itself, so the monitoring plan carries real methodological weight.
The enrolled population is limited to adults with paroxysmal atrial fibrillation, American Society of Anesthesiologists physical status class I to III, and written informed consent. Prior catheter ablation for atrial fibrillation or left atrial premature contractions is excluded, as are intracardiac or atrial thrombus and known allergy to iodinated contrast media. Those criteria keep the cohort relatively focused and help isolate the anesthesia question from other procedural confounders. The study start date is listed as June 1, 2026, with both primary completion and study completion estimated for June 2028.
What This Protocol Can and Cannot Answer Yet
PULSE-SED is still a protocol, not a results readout. It cannot yet show whether conscious sedation preserves rhythm control, lowers costs, or shortens recovery without increasing conversion or complications. What it does show is where the field is headed: toward testing whether a less resource-intensive anesthesia model can support the precision demands of modern atrial fibrillation ablation.
If the sedation strategy proves noninferior, the implications will extend beyond patient comfort. They could influence staffing models, lab scheduling, and access to pulsed field ablation in centers that do not have easy access to full general anesthesia support. If it falls short, the result would reinforce the idea that this energy source still needs the immobility and physiologic control that general anesthesia provides. Either outcome will answer a question that electrophysiology labs have been working around rather than settling outright: how much anesthesia does pulsed field ablation truly require?